Verona Pharma PLC (VRNA) reports significant sales growth for Ohtuvayre, but faces increased expenses and competition in the COPD market.

Q3 2024 Earnings Call Transcript November 4, 2024 Verona Pharma plc beats earnings expectations. Reported EPS is $-0.08819, ...

Ohtuvayre™ (ensifentrine) launch recorded Q3 net sales of $5.6 million and October net sales exceeded Q3 Through October more ...

Q3 2024 Earnings Conference Call November 4, 2024 9:00 AM ETCompany ParticipantsDavid Zaccardelli - President and ...

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Verona Pharma (VRNA – Research Report), boosting the price target to ...

H.C. Wainwright raised the firm’s price target on Verona Pharma (VRNA) to $42 from $36 and keeps a Buy rating on the shares post the Q3 ...

In other recent news, Verona Pharma has made significant strides with the FDA approval and launch of Ohtuvayre, a treatment for Chronic Obstructive Pulmonary Disease (COPD). Piper Sandler and Wells ...

Wells Fargo has set a $50 target on Verona Pharma, suggesting the potential of Ohtuvayre, a treatment for Chronic Obstructive Pulmonary Disease (COPD), could exceed market expectations.

Dupixent – which is due for a verdict from the FDA as a COPD therapy later this month – was cleared for adults with uncontrolled COPD with raised blood eosinophils, while Ohtuvayre can be used ...

Highlights:,Ohtuvayre™ generates $5.6 million in net sales in its first seven weeks, signaling a strong market entry.,October ...

Ohtuvayre™ (ensifentrine) is the Company's first commercial product and the first inhaled therapy for the maintenance treatment of COPD that combines bronchodilator and non-steroidal anti-inflammatory ...

In June 2024, the company received a significant boost with the approval of Ohtuvayre (ensifentrine) for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients.